Overview

ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer

Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The objective of the study is to investigate the safety and efficacy of ONO-4538 in subjects with stage IIIB/IV or recurrent non-small cell lung cancer unsuited to radical radiotherapy and resistant to a platinum-based chemotherapeutic regimen.
Phase:
Phase 2
Details
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Treatments:
Antibodies, Monoclonal
Nivolumab